Cargando…
Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs
BACKGROUND: Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. METHODS: Based on pre-treatment flea counts, do...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049393/ https://www.ncbi.nlm.nih.gov/pubmed/32113466 http://dx.doi.org/10.1186/s13071-020-3944-3 |
_version_ | 1783502429581475840 |
---|---|
author | Kryda, Kristina Mahabir, Sean P. Carter, Lori Everett, William R. Young, David R. Meyer, Leon Thys, Mirjan Chapin, Sara Holzmer, Susan J. Becskei, Csilla |
author_facet | Kryda, Kristina Mahabir, Sean P. Carter, Lori Everett, William R. Young, David R. Meyer, Leon Thys, Mirjan Chapin, Sara Holzmer, Susan J. Becskei, Csilla |
author_sort | Kryda, Kristina |
collection | PubMed |
description | BACKGROUND: Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. METHODS: Based on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs. RESULTS: Efficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study. CONCLUSIONS: A single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose. |
format | Online Article Text |
id | pubmed-7049393 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70493932020-03-05 Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs Kryda, Kristina Mahabir, Sean P. Carter, Lori Everett, William R. Young, David R. Meyer, Leon Thys, Mirjan Chapin, Sara Holzmer, Susan J. Becskei, Csilla Parasit Vectors Research BACKGROUND: Five studies were conducted to evaluate a novel oral combination tablet containing sarolaner, moxidectin and pyrantel (Simparica Trio™), for efficacy against induced flea infestations, speed of kill and effects on flea reproduction on dogs. METHODS: Based on pre-treatment flea counts, dogs were randomly allocated to treatment with a single, oral dose of either placebo or Simparica Trio™ at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt) on Day 0. All dogs were infested with approximately 100 unfed, adult fleas (C. felis or C. canis) prior to treatment and weekly for 5 weeks post-treatment. In Studies 1, 2 and 3, the number of viable fleas were comb-counted at 24 h after treatment and after each weekly infestation; Study 2 also included groups treated with tablets containing sarolaner-alone (1.2 mg/kg), moxidectin-alone (24 µg/kg) or pyrantel-alone (5 mg/kg). In Study 4, flea counts were conducted at 3, 4, 8 and 12 h after treatment and subsequent weekly infestations to establish speed of kill. In Study 5 (flea reproduction), dogs were housed in an enclosure designed to facilitate collection of flea eggs. RESULTS: Efficacy of Simparica Trio™ against C. felis was ≥ 99.7% and against C. canis was 100% at 24 h after treatment and after subsequent infestations for at least 35 days. Treatment with sarolaner-alone had similar efficacy to Simparica Trio™, while moxidectin-alone and pyrantel-alone were no different from placebo at most time points. In Study 4, significant flea killing started at 4 h after treatment; by 8 h after treatment, all treated dogs were free of fleas. Following weekly re-infestation, the combination product reduced fleas by ≥ 97.8% within 12 h for 28 days. Simparica Trio™ reduced flea egg-laying by 100% for 35 days. No treatment-related adverse reactions occurred in any study. CONCLUSIONS: A single dose of Simparica Trio™ at the recommended minimum dose provided highly efficacious and rapid treatment within 4 h of existing flea infestations and persistent control of fleas on dogs for 5 weeks. The efficacy against fleas resulted in 100% prevention of flea reproduction for over a month following a single oral dose. BioMed Central 2020-03-01 /pmc/articles/PMC7049393/ /pubmed/32113466 http://dx.doi.org/10.1186/s13071-020-3944-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Kryda, Kristina Mahabir, Sean P. Carter, Lori Everett, William R. Young, David R. Meyer, Leon Thys, Mirjan Chapin, Sara Holzmer, Susan J. Becskei, Csilla Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title | Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title_full | Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title_fullStr | Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title_full_unstemmed | Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title_short | Laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (Simparica Trio™) for the treatment and control of flea infestations on dogs |
title_sort | laboratory studies evaluating the efficacy of a novel orally administered combination product containing sarolaner, moxidectin and pyrantel (simparica trio™) for the treatment and control of flea infestations on dogs |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049393/ https://www.ncbi.nlm.nih.gov/pubmed/32113466 http://dx.doi.org/10.1186/s13071-020-3944-3 |
work_keys_str_mv | AT krydakristina laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT mahabirseanp laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT carterlori laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT everettwilliamr laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT youngdavidr laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT meyerleon laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT thysmirjan laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT chapinsara laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT holzmersusanj laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs AT becskeicsilla laboratorystudiesevaluatingtheefficacyofanovelorallyadministeredcombinationproductcontainingsarolanermoxidectinandpyrantelsimparicatrioforthetreatmentandcontroloffleainfestationsondogs |